l-ap4

L-APB is an effective and specific agonist for the group III mGluRs (EC50s: 0.13, 0.29, 1.0, 249 μM for mGlu4, mGlu8, mGlu6, and mGlu7 receptors, respectively).

L-AP4 (L-APB) monohydrate is a potent and specific agonist for group III mGluRs, with EC50s of 0.13, 0.29, 1.0, and 249 μM for mGlu4, mGlu8, mGlu6, and mGlu7 receptors, respectively [1][2].

Broad spectrum EAA ligand

Group III mGlu receptor agonist

DL-AP4, also known as 2-Amino-4-phosphonobutyric acid, is a competitive glutamate antagonist with defined binding affinity that is widely used to selectively inhibit glutamatergic neurotransmission, making it an essential experimental compound for probing synaptic signaling mechanisms and functional circuitry in central nervous system and visual system research.

MSOP is a selective antagonist of group III metabotropic glutamate receptor (KD of 51 μM for the L-AP4-sensitive presynaptic mGluR).

Maraviroc (UK-427857, Selzentry) belongs to small molecule drugs and is a C-C chemokine receptor 5 antagonist with oral activity and selectivity. This compound is used for the treatment of HIV-1 infection and has also shown anti-inflammatory, neuroprotective, and potential antitumor synergistic effects in research.

MPPG is a selective L-AP4-sensitive receptor antagonist (kD=9.2 μM).